Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction (Q48156451)

9 February 2018

title

Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction (English)

1 reference

9 February 2018

Heart failure with preserved ejection fraction

0 references

0 references

1 reference

1 reference

Jeremy Cypen

1

1 reference

9 February 2018

Tariq Ahmad

series ordinal

2

1 reference

9 February 2018

Jeffrey M Testani

series ordinal

3

1 reference

9 February 2018

Adam D DeVore

series ordinal

4

1 reference

9 February 2018

publication date

12 August 2017

1 reference

9 February 2018

Current heart failure reports

published in

1 reference

9 February 2018

volume

14

1 reference

9 February 2018

issue

5

1 reference

9 February 2018

page(s)

434-443

1 reference

9 February 2018

https://api.crossref.org/works/10.1007/S11897-017-0358-4

1 reference

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Spironolactone for heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Therapeutic implications of biomarkers in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Metabolomic fingerprint of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Systolic and diastolic heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

C-type natriuretic peptide in vascular physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Urinary C-type natriuretic peptide: a new heart failure biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Cardiac troponin and outcome in acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognosis of new-onset heart failure outpatients and collagen biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

C-reactive protein in heart failure: prognostic value and the effect of valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

C-reactive protein as a predictor of improvement and readmission in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Neopterin levels are independently associated with cardiac remodeling in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Growth differentiation factor 15 in heart failure: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

The Current and Potential Clinical Relevance of Heart Failure Biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Current and novel renal biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Challenges in using circulating miRNAs as cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11897-017-0358-4

21 January 2018

1 reference

12 December 2020

Adrenomedullin--physiological regulator of the cardiovascular system or biochemical curiosity?

1 reference

12 December 2020

Biomarkers and diagnostics in heart failure

1 reference

12 December 2020

Neopterin as a prognostic marker in patients with chronic heart failure.

1 reference

12 December 2020

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

12 December 2020

C-type natriuretic peptide: the endothelial component of the natriuretic peptide system

1 reference

12 December 2020

Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction

1 reference

12 December 2020

Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction

1 reference

12 December 2020

B-type natriuretic peptide in heart failure

1 reference

12 December 2020

10.1007/S11897-017-0358-4

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018